SIO GENE THERAPIES INC (SIOX) Stock Analyst Ratings

USA Nasdaq NASDAQ:SIOX • US8293991043

0.415 USD
+0.01 (+2.09%)
At close: Mar 22, 2023
0.4151 USD
+0 (+0.02%)
After Hours: 3/22/2023, 8:00:04 PM
Buy % Consensus

86

ChartMill assigns a Buy % Consensus number of 86% to SIOX. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 5.1. This target is 1128.92% above the current price.
  • SIOX was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about SIOX.
  • In the previous month the buy percentage consensus was at a similar level.
  • SIOX was analyzed by 7 analysts. More opinions would make the average more meaningful.
SIOX Historical Analyst RatingsSIOX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.425.055.105.105.25 - 1,116.87% 1,128.92% 1,128.92% 1,165.06%
SIOX Current Analyst RatingSIOX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2022-04-28 Cantor Fitzgerald Downgrade Overweight -> Neutral
2022-04-28 HC Wainwright & Co. Downgrade Buy -> Sell
2022-02-01 SVB Leerink Downgrade Outperform -> Market Perform
2022-02-01 HC Wainwright & Co. Maintains Buy
2021-10-21 HC Wainwright & Co. Maintains Buy
2021-08-12 SVB Leerink Maintains Outperform
2021-06-15 BTIG Initiate Buy
2021-04-30 HC Wainwright & Co. Initiate Buy

SIO GENE THERAPIES INC / SIOX FAQ

What is the average price target for SIO GENE THERAPIES INC (SIOX) stock?

7 analysts have analysed SIOX and the average price target is 5.1 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.415.


What is the consensus rating for SIOX stock?

The consensus rating for SIO GENE THERAPIES INC (SIOX) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.